Venus Medtech Hangzhou Inc (2500) - Product Pipeline Analysis, 2022 Update

Summary

Venus Medtech HangZhou Inc (Venus MedTech) is a medical device company that focus on development and commercialization of transcatheter heart valve products for structural heart diseases. The company's product portfolio includes venusA- valve, venusP- valve, V8/TAV8, and TriGUARD3 CEP device. It's products find applications in transcatheter aortic valve replacement system, anti-embolic distal brain protection device, TAV8 balloon dilatation catheter, transcatheter prosthetic pulmonary valve system, TMVr&TTVr mitral and tricuspid valve repair and replacement, RDN therapy, hypertrophic cardiomyopathy, transcatheter pulmonary valve replacement, transcatheter mitral valve replacement and transcatheter tricuspid valve replacement mainly associated with aortic stenosis and pulmonic, mitral and tricuspid regurgitation. Venus MedTech is headquartered in Binjiang, Hangzhou, China.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Venus Medtech Hangzhou Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Venus Medtech Hangzhou Inc Company Overview
Venus Medtech Hangzhou Inc Company Snapshot
Venus Medtech Hangzhou Inc Pipeline Products and Ongoing Clinical Trials Overview
Venus Medtech Hangzhou Inc – Pipeline Analysis Overview
Venus Medtech Hangzhou Inc - Key Facts
Venus Medtech Hangzhou Inc - Major Products and Services
Venus Medtech Hangzhou Inc Pipeline Products by Development Stage
Venus Medtech Hangzhou Inc Ongoing Clinical Trials by Trial Status
Venus Medtech Hangzhou Inc Pipeline Products Overview
AR Valve
AR Valve Product Overview
Cardiovalve Transcatheter Tricuspid Valve System
Cardiovalve Transcatheter Tricuspid Valve System Product Overview
Cardiovalve Transcatheter Tricuspid Valve System Clinical Trial
Cardiovalve Transfemoral Mitral Valve System
Cardiovalve Transfemoral Mitral Valve System Product Overview
Cardiovalve Transfemoral Mitral Valve System Clinical Trial
Lim Transseptal System
Lim Transseptal System Product Overview
Limbus
Limbus Product Overview
Small Incision Surgical Valve
Small Incision Surgical Valve Product Overview
Transapical Trinity Aortic Valve Implantation System
Transapical Trinity Aortic Valve Implantation System Product Overview
Transcatheter Tricuspid Valve Replacement Device
Transcatheter Tricuspid Valve Replacement Device Product Overview
Transfemoral Trinity Aortic Valve Implantation System
Transfemoral Trinity Aortic Valve Implantation System Product Overview
Tresillo System
Tresillo System Product Overview
TriGUARD3 Cerebral Embolic Protection Device
TriGUARD3 Cerebral Embolic Protection Device Product Overview
Tumbao EndoVascular Aortic Repair System
Tumbao EndoVascular Aortic Repair System Product Overview
Venus PowerX Valve
Venus PowerX Valve Product Overview
Venus Vitae Valve
Venus Vitae Valve Product Overview
Venus Vitae Valve Clinical Trial
Venus-Neo
Venus-Neo Product Overview
VenusA-Plus
VenusA-Plus Product Overview
VenusA-Valve
VenusA-Valve Product Overview
VenusA-Valve Clinical Trial
VenusP-Valve
VenusP-Valve Product Overview
VenusP-Valve Clinical Trial
Venus Medtech Hangzhou Inc - Key Competitors
Venus Medtech Hangzhou Inc - Key Employees
Venus Medtech Hangzhou Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Recent Developments
Venus Medtech Hangzhou Inc, Recent Developments
Mar 18, 2022: Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system
Sep 29, 2021: Venus Medtech Hangzhou Announces 2021 Interim Report
Aug 31, 2021: Venus Medtech Announces Interim Results for the Six Months Ended June 30, 2021
Mar 25, 2021: Keystone Heart and InterValve Medical enter distribution agreement for balloon aortic valvuloplasty portfolio
May 04, 2020: Venus Medtech and Opus Medical partner for TMVR and TTVR in China
May 02, 2020: Venus Medtech and Opus Medical Therapies announce partnership for transcatheter mitral valve replacement (TMVR) and transcatheter tricuspid valve replacement (TTVR) in greater China market
Mar 11, 2020: Keystone Heart secures CE Mark for cerebral embolic protection device
Feb 21, 2020: Cardiovalve’s Transcatheter Tricuspid Valve System gets FDA approval
Sep 20, 2018: Cardiovalve announces AHEAD US study for Transcatheter Mitral Valve Replacement System
Jun 14, 2018: Venus Medtech launches global advisor board to target for international market
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Venus Medtech Hangzhou Inc Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Venus Medtech Hangzhou Inc Pipeline Products by Equipment Type
Table 3: Venus Medtech Hangzhou Inc Pipeline Products by Indication
Table 4: Venus Medtech Hangzhou Inc, Key Facts
Table 5: Venus Medtech Hangzhou Inc, Major Products and Services
Table 6: Venus Medtech Hangzhou Inc Number of Pipeline Products by Development Stage
Table 7: Venus Medtech Hangzhou Inc Pipeline Products Summary by Development Stage
Table 8: Venus Medtech Hangzhou Inc Ongoing Clinical Trials by Trial Status
Table 9: Venus Medtech Hangzhou Inc Ongoing Clinical Trials Summary
Table 10: AR Valve - Product Status
Table 11: AR Valve - Product Description
Table 12: Cardiovalve Transcatheter Tricuspid Valve System - Product Status
Table 13: Cardiovalve Transcatheter Tricuspid Valve System - Product Description
Table 14: Cardiovalve Transcatheter Tricuspid Valve System - Safety and Performance of the Cardiovalve TR Replacement System for Tricuspid Regurgitation
Table 15: Cardiovalve Transfemoral Mitral Valve System - Product Status
Table 16: Cardiovalve Transfemoral Mitral Valve System - Product Description
Table 17: Cardiovalve Transfemoral Mitral Valve System - Cardiovalve Transfemoral Mitral Valve System in Patients at High Surgical Risk with Severe Mitral Regurgitation
Table 18: Cardiovalve Transfemoral Mitral Valve System - Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation
Table 19: Cardiovalve Transfemoral Mitral Valve System - Early Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System
Table 20: Cardiovalve Transfemoral Mitral Valve System - European Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System: AHEAD Study
Table 21: Cardiovalve Transfemoral Mitral Valve System - Evaluation of a Transcatheter Mitral Valve Replacement System for the Treatment of Severe Mitral Regurgitation with High Surgical Risk: A Chinese Feasibility Study
Table 22: Lim Transseptal System - Product Status
Table 23: Lim Transseptal System - Product Description
Table 24: Limbus - Product Status
Table 25: Limbus - Product Description
Table 26: Small Incision Surgical Valve - Product Status
Table 27: Small Incision Surgical Valve - Product Description
Table 28: Transapical Trinity Aortic Valve Implantation System - Product Status
Table 29: Transapical Trinity Aortic Valve Implantation System - Product Description
Table 30: Transcatheter Tricuspid Valve Replacement Device - Product Status
Table 31: Transcatheter Tricuspid Valve Replacement Device - Product Description
Table 32: Transfemoral Trinity Aortic Valve Implantation System - Product Status
Table 33: Transfemoral Trinity Aortic Valve Implantation System - Product Description
Table 34: Tresillo System - Product Status
Table 35: Tresillo System - Product Description
Table 36: TriGUARD3 Cerebral Embolic Protection Device - Product Status
Table 37: TriGUARD3 Cerebral Embolic Protection Device - Product Description
Table 38: Tumbao EndoVascular Aortic Repair System - Product Status
Table 39: Tumbao EndoVascular Aortic Repair System - Product Description
Table 40: Venus PowerX Valve - Product Status
Table 41: Venus PowerX Valve - Product Description
Table 42: Venus Vitae Valve - Product Status
Table 43: Venus Vitae Valve - Product Description
Table 45: Venus-Neo - Product Status
Table 46: Venus-Neo - Product Description
Table 47: VenusA-Plus - Product Status
Table 48: VenusA-Plus - Product Description
Table 49: VenusA-Valve - Product Status
Table 50: VenusA-Valve - Product Description
Table 51: VenusA-Valve - Venus Panorama II Post-marketing Registry Study
Table 52: VenusP-Valve - Product Status
Table 53: VenusP-Valve - Product Description
Table 54: VenusP-Valve - Study on Self-expanding Transcatheter Pulmonic Valve Replacement with VenusP-Valve in for the Treatment of Severe Pulmonary Regurgitation in Patients after Congenital Heart Defects (CHD) Procedure with Native Right Ventricular Outflow Tract (RVOT)
Table 55: VenusP-Valve - Study on the Treatment of Severe Pulmonary Regurgitation in Patients by Self-expanding Transcatheter Pulmonic Valve Replacement with VenusP-Valve
Table 56: Venus Medtech Hangzhou Inc, Key Employees
Table 57: Venus Medtech Hangzhou Inc, Subsidiaries
Table 58: Venus Medtech Hangzhou Inc, Joint Venture
Table 59: Glossary
List of Figures
Figure 1: Venus Medtech Hangzhou Inc Pipeline Products by Equipment Type
Figure 2: Venus Medtech Hangzhou Inc Pipeline Products by Development Stage
Figure 3: Venus Medtech Hangzhou Inc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings